Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
BMC Cancer ; 12: 520, 2012 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-23151147

RESUMEN

BACKGROUND: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT) antigens have became promising targets. METHODS: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of colon cancer. RESULTS: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the same test. CONCLUSION: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for cancer patients.


Asunto(s)
Antígenos de Neoplasias/sangre , Antígenos de Neoplasias/inmunología , Proteínas de Microtúbulos/sangre , Proteínas de Microtúbulos/inmunología , Neoplasias/inmunología , Testículo/inmunología , Formación de Anticuerpos , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Clonación Molecular/métodos , ADN Complementario/genética , Humanos , Masculino , Proteínas de Microtúbulos/genética , Proteínas de Microtúbulos/metabolismo , Neoplasias/sangre , Neoplasias/genética , Neoplasias/metabolismo , Pruebas Serológicas/métodos , Transcriptoma/genética , Transcriptoma/inmunología
2.
Cancer Lett ; 301(1): 57-62, 2011 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-21094583

RESUMEN

Serological analysis of a recombinant cDNA expression library (SEREX) derived from two lung adenocarcinoma cancer cell lines using autologous sera led to the isolation of 41 positive cDNA clones comprising 28 different antigens. They coded for a variety of nuclear and cytoplasmic proteins. Among the antigens, nucleoporin 107 (NUP107) was isolated most frequently (5 of 41 clones). The second most frequently isolated antigen was coded for by C21orf58 (4 of 41 clones). During serological analysis of selected antigens based on their reactivity to sera from normal individuals and lung cancer patients, none of the antigens showed a cancer-restricted recognition pattern. However, five genes including NUP107 showed higher expression when we examined the changes in gene expression in five different adenocarcinoma cell lines, including those used in SEREX, compared with their levels in normal lung tissues by cDNA microarray analysis. On the other hand, the expression levels of five genes including C21orf58 were down regulated in all adenocarcinoma cell lines. This SEREX study combining comprehensive gene expression assays has added to the growing list of lung cancer antigens, which may aid the development of diagnostic and immunotherapeutic reagents for patients with lung cancer.


Asunto(s)
Adenocarcinoma/inmunología , Anticuerpos Antineoplásicos/inmunología , Antígenos de Neoplasias/aislamiento & purificación , Biblioteca de Genes , Neoplasias Pulmonares/inmunología , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/inmunología , Línea Celular Tumoral , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA